Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe + Atorvastatin in Hypercholesterolemia with CHD
NCT00650689Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- May 2003
- Primary completion
- Dec 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe in hypercholesterolemia (2 arms), sponsored by Organon & Co. Primary endpoint: Low-Density Lipoprotein Cholesterol at 6 weeks. Started May 2003; status: completed.
02
Drugs
ezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00650689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00650689.